DexCom, Inc.

DXCM
$70.14 (+ $1.49 + 2.17%)
Last updated: 2026-06-27 15:00 UTC
DXCM Metrics
Exchange
🇺🇸 NASDAQ XNGS
Nasdaq/NGS (Global Select Market)United StatesAmerica/New_York
SectorHealthcare
IndustryMedical Devices
ISINUS2521311074
CUSIP252131107
Market Price70.14
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E Ratio37.42
EPS1.8
Market Cap$26.4B
Book Value6.99
Price to Book9.635
Beta1.51
52w High93.25
52w Low54.11
Next Earnings DateN/A

DexCom, Inc. trades under ticker DXCM on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US2521311074, CUSIP 252131107.

About the Company
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Price History